Skip to main content

Peer Review reports

From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

Original Submission
30 Jul 2022 Submitted Original manuscript
7 Nov 2022 Reviewed Reviewer Report - Xinwei Han
30 Dec 2022 Reviewed Reviewer Report - Miki Takenaka Sato
6 Jan 2023 Author responded Author comments - Chuansheng Zheng
10 Jan 2023 Author responded Author comments - Chuansheng Zheng
Resubmission - Version 2
6 Jan 2023 Submitted Manuscript version 2
14 Jan 2023 Reviewed Reviewer Report - Xinwei Han
23 Jan 2023 Reviewed Reviewer Report - Miki Takenaka Sato
24 Jan 2023 Author responded Author comments - Chuansheng Zheng
Resubmission - Version 3
24 Jan 2023 Submitted Manuscript version 3
28 Jan 2023 Reviewed Reviewer Report - Miki Takenaka Sato
1 Feb 2023 Author responded Author comments - Chuansheng Zheng
Resubmission - Version 4
1 Feb 2023 Submitted Manuscript version 4
2 Feb 2023 Author responded Author comments - Chuansheng Zheng
Resubmission - Version 5
2 Feb 2023 Submitted Manuscript version 5
Publishing
20 Mar 2023 Editorially accepted
24 Mar 2023 Article published 10.1186/s12885-023-10754-0

You can find further information about peer review here.

Back to article page